This is a working overview of circadian rhythm, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-09. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
Athletes competing in power sports, bodybuilding, professional wrestling, mixed martial arts, swimming, baseball, strength sports, track and field, cycling, soccer, weight lifting, skiing and endurance sports have been said to abuse human growth hormone, including in combination with other performance-enhancing drugs such as androgenic anabolic steroids including testosterone, certain products which claim to enhance HGH, and erythropoietin (among others). There has never been an adequately large randomized controlled trial showing definitively that HGH provides benefits to athletes and that there are no significant adverse drug reactions; there have been many small studies and several of these studies were recently reviewed and analyzed in a meta-analysis. While the authors indicated that the meta-analysis was limited by the fact that few of the included studies evaluated athletic performance and by the fact that dosing protocols in the studies may not reflect real-world doses and regimens, their conclusions were as follows:
On 16 November, Olivey decided that holding the point any longer was pointless and ordered his men to split up, escape by any means possible and re-assemble in Cairo. Over half of the unit reached Egypt.
== Further reading == Theravada Walpola Rahula (1974), What the Buddha Taught P. A. Payutto, Dependent Origination: The Buddhist Law of Conditionality (translation for the fourth chapter of P. A. Payutto's Buddhadhamma) Ajahn Sucitto (2010). Turning the Wheel of Truth: Commentary on the Buddha's First Teaching. Shambhala. (pages 61–76) Jackson, Peter A. (2003), Buddhadasa. Theravada Buddhism and Modernist reform in Thailand, Silkworm Books Ajahn Amaro (2021), Catastrophe/Apostrophe: The Buddha's Teachings on Dependent Origination/Cessation, Amaravati Publications Tibetan Buddhism Chogyam Trungpa (1972). "Karma and Rebirth: The Twelve Nidanas, by Chogyam Trungpa Rinpoche." Karma and the Twelve Nidanas, A Sourcebook for the Shambhala School of Buddhist Studies. Vajradhatu Publications. Dalai Lama (1992). The Meaning of Life, translated and edited by Jeffrey Hopkins, Boston: Wisdom. Geshe Sonam Rinchen (2006). How Karma Works: The Twelve Links of Dependent Arising. Snow Lion Khandro Rinpoche (2003). This Precious Life. Shambala Thrangu Rinpoche (2001). The Twelve Links of Interdependent Origination. Nama Buddha Publications. Scholarly Frauwallner, Erich (1973), "Chapter 5. The Buddha and the Jina", History of Indian Philosophy: The philosophy of the Veda and of the epic. The Buddha and the Jina. The Sāmkhya and the classical Yoga-system, Motilal Banarsidass Bucknell, Roderick S.
Sources: en.wikipedia.org
=== Score of the BLOSUM matrices === A scoring matrix or a table of values is required for evaluating the significance of a sequence alignment, such as describing the probability of a biologically meaningful amino-acid or nucleotide residue-pair occurring in an alignment. Typically, when two nucleotide sequences are being compared, all that is being scored is whether or not two bases are the same at one position. All matches and mismatches are respectively given the same score (typically +1 or +5 for matches, and -1 or -4 for mismatches). But it is different for proteins. Substitution matrices for amino acids are more complicated and implicitly take into account everything that might affect the frequency with which any amino acid is substituted for another. The objective is to provide a relatively heavy penalty for aligning two residues together if they have a low probability of being homologous (correctly aligned by evolutionary descent). Two major forces drive the amino-acid substitution rates away from uniformity: substitutions occur with the different frequencies, and lessen functionally tolerated than others. Thus, substitutions are selected against. Commonly used substitution matrices include the blocks substitution (BLOSUM) and point accepted mutation (PAM) matrices. Both are based on taking sets of high-confidence alignments of many homologous proteins and assessing the frequencies of all substitutions, but they are computed using different methods.
By 1830, the German mathematician Carl Friedrich Gauss had determined the boundary conditions governing capillary action (i.e., the conditions at the liquid-solid interface). In 1871, the British physicist Sir William Thomson (later Lord Kelvin) determined the effect of the meniscus on a liquid's vapor pressure—a relation known as the Kelvin equation. German physicist Franz Ernst Neumann (1798–1895) subsequently determined the interaction between two immiscible liquids. Albert Einstein's first paper, which was submitted to Annalen der Physik in 1900, was on capillarity.
Exhumation, or disinterment, is the act of digging something up, especially a corpse. This is most often done to relocate a body to a different burial spot; families may make this decision to locate the deceased in a more pertinent or convenient place. In shared family burial sites (e.g. a married couple), if the previously deceased person has been buried for an insufficient period of time, the second body may be buried elsewhere until it is safe to relocate it to the shared grave. Exhumation of human remains occur for a number of other reasons, including body identification or as part of a criminal investigation. If an individual dies in suspicious circumstances, police may request exhumation to determine the cause of death. Exhumations may also occur via grave robbery or as an act of desecration. In rare, historical cases (e.g. Pope Formosus or Oliver Cromwell), a body may be exhumed for posthumous execution, dissection, or gibbeting. Notable individuals may be exhumed to answer historical questions. Exhumation by archaeologists enables the study of remains, as with many ancient Egyptian mummies that have been put on public display. In most jurisdictions, a legal exhumation usually requires a court order or permission by the next of kin of the deceased. U.S. law allows disinterment "only for the most compelling of reasons" and with the permission of close relatives and the cemetery official. Also in many countries, permits are required by some governing agency to legally conduct a disinterment.
They allow a continuous infusion of small amounts of insulin to be delivered through the skin around the clock. They also have the ability to give bolus doses when a person eats or has elevated blood glucose levels. They are also capable to being used in conjunction with continuous glucose monitors for optimal glucose management. This is very similar to how the pancreas works, but these pumps lack a continuous "feed-back" mechanism. Thus, the user is still at risk of giving too much or too little insulin unless blood glucose measurements are made.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.